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Abstract The ERM proteins, ezrin, radixin and moesin, provide
regulated linkage of the cytoskeleton with the plasma membrane,
particularly in cell surface projections. Ezrin and moesin were
found co-expressed, and radixin was not detected, in human
blood lymphocytes, monocytes and neutrophils. Moesin is the
quantitatively dominant ERM protein in these cells and the only
one in platelets. Because Ca2+ signaling pathways involving
calpain cleavages are important in blood cells, we examined
ERM protein sensitivity to this protease. A striking difference
was discovered: sensitivity of ezrin and resistance of moesin (and
radixin) to calpain. In intact stimulated lymphocytes, ezrin was
cleaved, while moesin was not, strongly suggesting that
differential sensitivity to calpain contributes to specialized
functions of these proteins.
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1. Introduction
Ezrin, radixin, and moesin, the ERM family proteins, local-
ize to, and support, cell surface projections by forming oligo-
meric head-to-tail structures linking the underlying cytoskele-
ton with the plasma membrane [1,2] The proteins are V75%
identical in amino acid sequence. As members (with talin and
merlin) of the 4.1 band superfamily, the ERM proteins share
that family’s structural organization: a globular N-terminal
domain, an K-helical segment and a highly charged C-terminal
domain. Their physiological expression patterns di¡er,
strongly suggesting that the proteins are functionally non-
identical [3^5], yet the ERM proteins undergo similar inter-
actions when examined as pure proteins and in cell lines and
transfected cells [1,2]. The N-terminal domain associates with
the plasma membrane and the C-terminal domain with the
cytoskeleton [6]. The ERM proteins are essential, for example,
for the assembly of actin ¢laments and focal adhesion com-
plexes mediated by the GTPases Rho and Rac [7]. ERM pro-
teins are found also as dormant monomers in which the N-
terminus is associated intramolecularly with the C-terminus
[8]. The monomers are subject to complex regulatory mecha-
nisms leading to conformational activation and formation of
oligomeric surface linking structures [9].
The focus of our laboratory is blood cells, particularly lym-
phocytes and platelets, and we are interested therefore in the
molecules that regulate their surface projections such as mi-
crovilli, ¢lopodia and lamellipodia. Microvilli, the slender
projections that dominate the surface of circulating lympho-
cytes, function to monitor the blood vessel wall and serve as
the locus of adhesion and morphological changes leading to
extravasation and activation [10]. The relevance of ERM pro-
teins was indicated by the disappearance of lymphoid cell
microvilli on treatment with antisense nucleotides to the three
ERM proteins or with single antisense oligonucleotides to
moesin [11]. Blood platelets, in contrast to lymphocytes, are
smooth-surfaced in the circulating state and, in response to
agonists, rapidly develop long ¢lopodia and ru¥ing lamellae,
which contribute to formation of the platelet plug, a crucial
event in hemostasis.
As a basis for understanding the role of ERM proteins in
lymphocyte and platelet activation events, the present study
was undertaken to determine the expression pattern and func-
tional properties of these proteins in blood cells.
2. Materials and methods
2.1. Reagents
Prostacyclin (PGI2), phorbol myristate acetate (PMA), bovine se-
rum albumin, Histopaque 1077 and dextran were from Sigma Chem-
icals, St. Louis, MO; leupeptin from Boehringer Mannheim Biochem-
icals, Indianapolis, IN; SDS and NP-40 from BDH Chemicals,
Richmond, CA; and ionomycin, calpeptin and W-procalpain (calpain
I, porcine erythrocyte, 120 U/mg) from Calbiochem, San Diego, CA.
2.2. Antibodies
Monospeci¢c anti-ezrin and anti-moesin rabbit antibodies were af-
¢nity-puri¢ed as described [12]. Puri¢ed anti-radixin antibodies were
from rabbits immunized with bacterially expressed GST-radixin.
Mouse monoclonal antibodies (mAb) included B27D8, an IgG1 rec-
ognizing W-calpain heavy chain [13], and clone 38 anti-moesin amino
acids 554^564, an IgG1 from Transduction Labs, Lexington, KY.
A⁄nity-puri¢ed goat anti-rabbit and rabbit anti-mouse immunoglo-
bulins were from Cappel, Durham, NC and Pierce Chemicals, Rock-
ford, IL, respectively.
2.3. Platelets
Freshly drawn blood from healthy consenting volunteers was col-
lected in acid-citrate-dextrose (ACD; NIH formula A) and centri-
fuged at 200Ug for 12 min at ambient temperature to separate pla-
telet-rich plasma (PRP). Additional ACD was added (1 part per
3 parts PRP), and the PRP was centrifuged at 800Ug for 15 min.
The platelets were resuspended in platelet bu¡er (10 mM N-Tris-(hy-
droxymethyl) methyl-2-aminoethane sulfonic acid, pH 7.2, 136 mM of
NaCl, 2.6 mM of KCl, 0.5 mM of NaH2PO4, 2 mM MgCl2, 0.1%
glucose, and after addition of ACD (10% of ¢nal volume), were pel-
leted at 800Ug for 10 min.
2.4. Lymphocytes and monocytes
The pelleted blood cells (after removal of PRP) were fractionated
by Histopaque-1077 density centrifugation as described [14]. The in-
terface lymphocytes and monocytes were harvested, and monocytes
depleted from the lymphocytes by adherence. The monocytes were
harvested from the tissue culture plates by dislodging with a rubber
policeman into cold Ca2/Mg2-free HBSS and washed.
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2.5. Neutrophils
Pelleted blood cells were combined 1:1 with 2% dextran in 150 mM
NaCl and incubated at V22‡C for 30 min to sediment erythrocytes.
The leukocyte-containing supernatant was aspirated; the cells were
collected by pelleting, layered onto Histopaque-1077 and centrifuged
at 800Ug for 40 min. The pelleted cells were washed in Ca2/Mg2-
free HBSS, and residual erythrocytes removed by water lysis.
2.6. Erythrocytes
After removal of PRP and the top half of the pelleted blood cells,
the remaining packed erythrocytes were suspended in 10 volumes of
Ca2/Mg2-free HBSS and washed by several cycles of centrifugation
for 10 min at 1300 rpm. The erythrocyte preparations contained 6 1
leukocyte per 5U103 erythrocytes.
2.7. Megakaryocytes
Megakaryocytes were isolated from bone marrow aspirates of vol-
unteer donors [15] by Histopaque-1077 fractionation and culturing to
remove adherent material. The non-adherent cells were incubated with
anti-GPIIIa (anti-CD61) (mAB Y2/5 from Dako, Carpenteria, CA)
and then with rabbit anti-mouse IgG coupled to magnetic beads (Dy-
nal, Lake Success, NY). The megakaryocytes were isolated magneti-
cally and examined by light microscopy.
2.8. Endothelial cells
Pooled umbilical vein endothelial cells were grown in primary cul-
ture [16] for three passages. At con£uence, the cells were quanti¢ed by
microscopic examination, washed and lysed by adding SDS sample
bu¡er (1% SDS, 62 mM Tris-HCl, pH 6.8, 2% mercaptoethanol, 2 mM
EGTA, 25 Wg/ml leupeptin) directly to the plate.
2.9. SDS electrophoresis
Lymphocytes, monocytes, neutrophils and HepG2 cells were lysed
at 15U106/ml, platelets at 5U108/ml, erythrocytes at 7U108/ml, en-
dothelial cells at V6U106/ml, and megakaryocytes at 105/ml in 1%
SDS, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 50 Wg/ml leupeptin,
2 mM DFP, 2% mercaptoethanol, 20 Wg/ml bromophenol blue, 10%
glycerol by ¢rst suspending the cells in 0.8 volumes of Tris-NaCl-
EGTA-DFP-leupeptin followed by addition of 0.2 volumes of SDS
and the remaining reagents and heating for s 3 min at 100‡C. The
SDS solubilization protocols for calpain reactions and stimulated lym-
phocytes are described below. Solubilized samples were fractionated
by SDS electrophoresis on 8% acrylamide gels (Novex, San Diego,
CA) using pH 8.3 running bu¡er [17].
2.10. Immunoblotting
Polypeptides were transferred to nitrocellulose at constant 80 mA at
V22‡C for 16 h. The membrane was blocked with 2% normal goat
serum in PBS/0.05% Tween-20 for 20 min, washed and incubated for
2 h with 20 ng/ml rabbit antibodies to moesin or ezrin or radixin. The
membranes were washed and incubated with 125I-labeled goat anti-
rabbit IgG (0.5^1.0 Wg/ml) for 1 h, washed and exposed to Phosphor-
screen, and bands were quanti¢ed using Phosphorimager Storm 860
and Image Quant v1.1 program (Molecular Dynamics, Sunnyvale,
CA). Alternatively, membranes blocked with 2% normal rabbit serum
were stained with B27D8 anti-calpain (ascites at 1:20 000) or clone 38
anti-moesin (125 ng/ml) and detected with 125I-labeled rabbit anti-
mouse IgG.
2.11. Quantitation of ezrin and moesin
Lysates of blood cells were examined by immunoblot in parallel
with dilutions of pure ezrin isolated from human placenta [18], which
served as an internal standard curve. Moesin was similarly quanti¢ed
using a standard curve of full-length moesin, which was expressed in
and puri¢ed from Escherichia coli using procedures identical to those
for full-length ezrin [19].
2.12. Calpain reactions in broken cell preparations
Platelets at 109/ml in Ca2/Mg2-free HBSS containing 1 mM of
EGTA and 2 mM mercaptoethanol were lysed by sonication [14],
clari¢ed by centrifugation and stored in aliquots at 380‡C. Lympho-
cytes (15U106/ml) and HeLa cells (25U106/ml) were lysed in 0.5%
NP-40, 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM DFP,
25 Wg/ml leupeptin, 2 mM EGTA and clari¢ed by centrifugation.
Platelet sonicates (or platelet sonicates combined 1:1 with lympho-
cyte lysate) were preincubated at V22‡C for 3 min; CaCl2 was added
to 6 mM and incubation continued at V22‡C for 0^30 min. The
reactions were stopped with an equal volume of 2USDS sample bu¡er
and heating at 100‡C for 2 min. HeLa cells lysates were combined 1:1
with W-procalpain (calpain I from porcine erythrocytes) in 20 mM
Tris-HCl, pH 7.4, 75 mM NaCl, 0.2 mM mercaptoethanol, and after
addition of CaCl2 (6 mM), were incubated at V22‡C for 0^20 min,
and processed as above. Pure ezrin or pure moesin at 40 Wg/ml was
treated with procalpain and Ca2 as described for HeLa cell lysates.
2.13. Lymphocyte stimulation
Lymphocytes at 1.5U107/ml in RPMI 1640 medium with 5% fetal
calf serum, 100 U/ml penicillin and 100 Wg/ml streptomycin were
precultured for V10 min at 37‡C prior to addition of PMA
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Fig. 1. Human hematopoietic cells and control cells examined for expression of ezrin, radixin and moesin. A: Immunoblots. Similar total pro-
tein levels were stained for ezrin (left panel), radixin (center panel) and moesin (right panel). Shown are L, lymphocytes; M, monocytes; N,
neutrophils ; P, platelets; E, erythrocytes; MK, bone marrow megakaryocytes and, as a control for radixin, H, HepG2 cells. Arrows indicate
ezrin and radixin migrating at 81 kDa and moesin at 77 kDa. B: Quantitation of ezrin and moesin in isolated cells (details in Section 2). Levels
of ezrin (left) and moesin (right) are expressed as Wg/mg of total cell protein. ‘EC’ indicates endothelial cells. Values are the mean of v 3 assays
of 2^3 lysates; S.E.M. was 6 5%.
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(10 ng/ml) and ionomycin (1 WM). After 0^30 min at 37‡C, the cells
were lysed by adding 5USDS sample bu¡er and heating at 100‡C. To
inhibit calpain action, the lymphocytes were preincubated with
50 Wg/ml calpeptin for 20 min at 37‡C prior to addition of PMA
and ionomycin.
2.14. Protein quantitation
Protein in cell lysates was quanti¢ed with Nano-Orange (N-6666
kits; Molecular Probes, Eugene, OR) using bovine albumin as stand-
ard. Fluorescence was measured with excitation at 485 nm and emis-
sion at 590 nm.
3. Results
3.1. Ezrin and moesin expression in blood cells
To determine the expression pattern of ERM proteins, im-
munoblots of isolated human blood cells were stained with
rabbit antibodies speci¢c for each protein. On analysis of
similar amounts of total cell protein, ezrin was found at read-
ily detectable levels in lymphocytes, monocytes and neutro-
phils and at low levels in erythrocytes (Fig. 1A, left).
Although ezrin was readily detected also in megakaryocytes,
the platelet precursor cells in bone marrow, it was not found
in platelets (Fig. 1A) in veri¢cation of a previous report [20].
The apparent lack of ezrin in platelets is unlikely to be due to
proteolysis because (i) the lysates were prepared with protease
inhibitors and (ii) SDS gels stained with Coomassie blue
showed no detectable degradation of platelet proteins (data
not shown). On staining with radixin-speci¢c antibodies, no
reactive protein was detected in lymphocytes, monocytes, neu-
trophils, platelets or erythrocytes, but was detected in HepG2
cells [21] used as positive control (Fig. 1A, center). Immuno-
blots with moesin-speci¢c antibodies detected moesin in lym-
phocytes, monocytes, neutrophils and also in platelets and
megakaryocytes (Fig. 1A, right).
3.2. Levels of ezrin and moesin in blood cells
Because the intensity of immunoblot signals depends only
partially on antigen density, we quanti¢ed ezrin and moesin in
blood cells by comparing their immunoblot signals to those of
known amounts of pure ezrin or moesin. Ezrin levels were
found to vary from a low of 6 0.1 Wg/mg cell protein in
erythrocytes and megakaryocytes to 0.5, 0.7 and 1.3 Wg/mg
protein, respectively, in neutrophils, monocytes and lympho-
cytes (Fig. 1B, left).
Surprisingly, moesin levels in blood cells were found to be
very high. Whereas endothelial cells, which were previously
noted to have a high moesin content [5,4], contain 1.5 Wg
moesin/mg cell protein, megakaryocytes have 1.8 Wg; platelets,
2.5 Wg; neutrophils, 3.0 Wg; monocytes, 4.0 Wg; and lympho-
cytes, the highest level, 4.8 Wg/mg cell protein (Fig. 1B, right).
Cumulatively, these ¢ndings identify moesin as the quantita-
tively dominant ERM protein in white blood cells and, as
previously reported, the sole ERM protein in platelets.
3.3. Ezrin and moesin di¡er in sensitivity to calpain in vitro
In this section, we compared moesin and ezrin for suscept-
ibility to proteolysis, a putative in vitro correlate of termina-
tion of ERM function (see Section 4). The neutral cysteine
protease calpain was examined because it is a known e¡ector
of Ca2-mediated platelet and lymphocyte activation path-
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Fig. 2. Sensitivity of ezrin, moesin and radixin to calpain. Broken
cell preparations were incubated at V22‡C for the indicated time
and analyzed by immunoblots. A: Platelet sonicates incubated with
Ca2. The left panel shows conversion of endogenous 80 kDa pro-
calpain (pro-calp) to active 76 kDa calpain (arrow); the right panel
shows moesin (M) unaltered after 15 min of calpain exposure. B:
Combined lymphocyte and platelet lysates incubated with Ca2. The
left panel shows time-dependent cleavage of ezrin (E) and formation
of the short-lived 55 kDa fragment (fr-55). The right panel shows
unaltered moesin (M) in the same reaction. C: HeLa cell lysate in-
cubated with pure procalpain and Ca2. The upper panel shows cal-
pain activation. The lower left panel, a blot stained with rabbit anti-
bodies that detect both ezrin and moesin, shows time-dependent
decrease of ezrin and unaltered moesin. The lower right panel shows
unaltered radixin (R) detected with speci¢c antibodies.
Fig. 3. Sensitivity of pure ezrin and moesin to calpain. Pure ezrin
and moesin were separately incubated with pure procalpain and
Ca2 at V22‡C for 20 min. A: Coomassie blue-stained gel shows
ezrin (E) incubated with 0, 5, 10 and 15 Wg/ml procalpain and moe-
sin (M) incubated with 0 and 15 Wg/ml procalpain. B: Immunoblot
stained with a mAb that recognizes a shared epitope shows ezrin
(E) and moesin (M) incubated with 0 and 80 Wg/ml procalpain.
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ways [22,23]. Calpain, an inactive proenzyme in resting cells,
is autoproteolytically activated on exposure to elevated Ca2.
Previous studies showed that ezrin is cleaved by calpain
[24,25] and the related 4.1 superfamily proteins talin [22]
and merlin [26] are also among the select calpain substrates;
moesin had not been examined.
To examine moesin’s sensitivity to calpain, we generated
platelet sonicates as an approximation of the intraplatelet en-
vironment and as a rich source of procalpain [27]. Addition of
Ca2 converted procalpain to active calpain, which was veri-
¢ed by altered SDS mobility of the calpain heavy chain (Fig.
2A, left). Coomassie blue-stained SDS gels demonstrated
cleavage of the endogenous calpain substrates actin binding
protein and talin [22] (data not shown). However, no degra-
dation of moesin was observed up to 15 min (Fig. 2A, right).
To verify moesin’s insensitivity to calpain by simultaneously
examining ezrin, lymphocyte lysates were combined with pla-
telet sonicates prior to activation of endogenous calpain.
Time-dependent degradation of ezrin began 1 min after
Ca2 addition, producing the previously described [24,25]
short-lived 55 kDa fragment (fr-55, Fig. 2B, left panel) ; ezrin
degradation was not observed when Ca2 was omitted or the
calpain inhibitor leupeptin added (data not shown). No deg-
radation of moesin was observed up to 15 min (Fig. 2B,
right).
Since the amounts of moesin and ezrin are unequal in the
combined lymphocyte/platelet lysates, we also examined ly-
sates of HeLa epithelioid cells, which contain comparable
amounts of ezrin and moesin. Pure W-procalpain (from por-
cine erythrocytes) was added and activated by addition of
Ca2. Immunoblots showed time-dependent activation of cal-
pain (Fig. 2C, upper panel). Ezrin underwent time-dependent
cleavage, and moesin in the same samples remained unaltered
(Fig. 2C, lower left panel). Since HeLa cells, unlike blood
cells, also express radixin, aliquots of the treated HeLa cell
lysates were also immunoblotted for radixin, which, like moe-
sin and unlike ezrin, was found unaltered after 15 min expo-
sure to calpain (Fig. 2C, lower right panel).
Finally, pure ezrin and moesin were separately incubated
with pure W-procalpain in the presence of Ca2. Coomassie
blue-stained gels revealed dose-dependent cleavage of ezrin by
10 and 15 Wg/ml calpain (Fig. 3A). The resistance of pure
moesin to 15 Wg/ml calpain was demonstrated by Coomassie
blue-stained gels (Fig. 3A, last lane), and its resistance to 80
Wg/ml calpain was demonstrated by immunoblot (Fig. 3B).
These cumulative ¢ndings verify the calpain sensitivity of ez-
rin by showing its e⁄cient and complete cleavage and dem-
onstrate that moesin (and also radixin) remains resistant even
to several-fold higher calpain levels.
3.4. Di¡erential fate of ezrin and moesin in intact cells
To examine the calpain sensitivity of ezrin and moesin in
intact blood cells, we focused on lymphocytes, which express
both ezrin and moesin and which respond to proliferation-
inducing stimuli by a Ca2 signaling pathway that includes
calpain activation [23]. Isolated lymphocytes were stimulated
by the combination of PMA, a protein kinase C activator,
and ionomycin, a Ca2 ionophore; this well-characterized T-
cell stimulus bypasses the T-cell receptor/CD3 complex and
induces lymphocyte proliferation after V48 h [28].
On culture with PMA and ionophore, a time-dependent
decrease was detected in the lymphocyte content of intact
ezrin (Fig. 4A); the change amounted to a 29 þ 5% decrease
after 30 min (n = 4) (Fig. 4A). In contrast, moesin was quan-
titatively recovered in the same cell lysates (Fig. 4A). Activa-
tion of endogenous lymphocyte calpain was veri¢ed (Fig. 4B).
When lymphocytes were pretreated with calpeptin, a cell-per-
meating calpain inhibitor [29], ezrin levels did not decrease.
After 30 min, the levels of intact ezrin remaining in calpeptin-
pretreated lymphocytes were 102 þ 4.5% and 100 þ 3.8% (n =
3), respectively, in cultures with and without PMA and
ionomycin, strongly suggesting that the decrease of ezrin
induced by PMA and ionomycin is calpain-dependent. These
¢ndings demonstrate that ezrin is cleaved in intact activated
lymphocytes in a calpain-dependent reaction and moesin re-
mains unaltered.
4. Discussion
Immunoblots with speci¢c antibodies detected ezrin and
moesin in white blood cells: lymphocytes, monocytes and
neutrophils, and also in megakaryocytes, platelet precursor
cells from bone marrow. Previous studies have shown that
the only ERM protein present in platelets is moesin [20],
and we have now quanti¢ed the level of moesin in all these
cells. Indeed, moesin expression levels in blood cells are high
by any standard, amounting in lymphocytes to V0.5% of
total cell protein. Radixin was not found in any blood cell
examined.
As a step toward understanding their function, we com-
pared the blood cell ERM proteins ezrin and moesin for sen-
sitivity to the protease calpain, an important e¡ector of Ca2
signaling and activation-associated morphological changes in
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Fig. 4. Cleavage of ezrin and persistence of moesin in blood lym-
phocytes stimulated with PMA plus ionomycin. Lymphocytes in se-
rum-containing medium were cultured with PMA and ionomycin.
At the indicated times, the cells were lysed, and ezrin, moesin and
calpain were examined by immunoblotting. A: Quantitation of ezrin
and moesin in treated cells expressed as percent relative to starting
cells. Data are the mean þ S.E.M. of four experiments with lympho-
cytes from di¡erent donors. B: Immunoblot from a representative
experiment demonstrating activation of endogenous lymphocyte cal-
pain.
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blood cells. Several in vitro approaches were used to examine
calpain sensitivity: platelet sonicates studied with endogenous
calpain to preserve the physiological environment, HeLa cell
lysates studied with exogenous calpain, which allowed com-
parable levels of ezrin and moesin to be examined, and also
pure moesin and ezrin treated with pure calpain. In all sys-
tems, a dramatic di¡erence was found in that ezrin was readily
and completely proteolysed, and moesin was insensitive even
at several-fold higher calpain levels. An advantage of the
HeLa cell system is that endogenous radixin, which was not
found in blood cells, could also be examined; radixin was also
resistant to calpain. Di¡erent sensitivity to calpain is one of
the few divergent biochemical reactions of ezrin and moesin,
and we propose that this feature provides a basis for non-
redundant functions of these proteins.
The ERM proteins have di¡erent expression patterns and
levels, as shown here for blood cells, strongly suggesting that
each has specialized or unique functions, yet the three proteins
are structurally similar and have been considered functionally
equivalent. These ¢ndings imply that the basis for specialized/
unique functions will be found at the level of regulatory
events, i.e. either selective recruitment of individual proteins
to form functional linker structures and/or selective termina-
tion of linker structures involving individual proteins.
Selective recruitment was suggested by the ¢nding that, in
cells expressing the three ERM proteins, each exhibited a
distinct receptor-speci¢c phosphorylation pattern, and thus
individual proteins might be recruited and functionally acti-
vated in response to di¡erent receptor signals [30]. Less ob-
vious is the interpretation of EGF-induced recruitment of
ezrin and moesin to transient membrane ru¥es in that both
proteins are recruited, but only ezrin is tyrosine-phosphoryl-
ated [18,12].
The hypothesis that di¡erent sensitivity to calpain provides
a basis for selective termination of ezrin’s and moesin’s spe-
cialized linker structures is supported by theoretical consider-
ations and experimental evidence. Since the ability of ezrin
and moesin to function as linker proteins requires sites in
the N-terminus that bind plasma membrane proteins and sites
in the C-terminus that bind the actin cytoskeleton [6], proteo-
lytic cleavage has the capacity to disrupt membrane-cytoske-
leton linkages. Evidence strongly suggesting that calpain sen-
sitivity su⁄ces as a basis for terminating ezrin’s linker
function is provided by studies in gastric parietal cells in
which ezrin cleavage by calpain was linked to inhibition of
proton secretion [24]. In endothelial cells, ezrin cleavage by
calpain was associated with stimulation of locomotion and
abolition of ezrin’s ability to associate with L-actin [25].
A related pathological example of calpain sensitivity serving
as the basis for termination of ERM-like function is provided
by merlin, a 4.1 band superfamily protein closely related to
the ERM proteins, sharingV65% amino acid identity over its
N-terminal domain [31]. Merlin functions as a tumor suppres-
sor. Tumors (schwannomas and meningiomas) arise in most
cases due to mutations of the merlin gene leading to non-
expression of merlin protein, but in other cases are due to
stable overactivation of the calpain system, which causes de-
pletion of merlin by proteolysis [26].
The present study demonstrated that ezrin and moesin of
blood lymphocytes exhibit a divergent response to signaling
involving Ca2 transients induced by PMA and Ca2 iono-
phore. Whereas ezrin was cleaved, moesin remained intact.
Similar results were obtained when lymphocytes were acti-
vated with the more physiological stimulus anti-CD3 mAb
(Shcherbina et al., in preparation). These ¢ndings suggest
that moesin, but not ezrin, retains the ability to function dur-
ing and subsequent to Ca2 signaling. Indeed, ezrin and moe-
sin may function sequentially to support di¡erent morpholog-
ical structures required as lymphocytes di¡erentiate, i.e. early
acting ezrin in resting cells and moesin contributing to surface
projections in lymphocytes that have undergone Ca2 signal-
ing and activation. Circulating lymphocytes are spheroidal
cells with a surface dominated by slender microvilli that serve
to monitor the vascular wall [10]. As part of the early re-
sponse to proliferation-inducing stimuli, lymphocytes undergo
cytoskeletal remodeling and become polarized [32^34]. In rest-
ing lymphocytes, ezrin and moesin were found by £uorescent
microscopy to co-localize in surface microvilli, and these
structures were rapidly disassembled on cell activation
(Shcherbina et al., in preparation). Since ezrin and moesin
can form heterodimers in vivo [35], early acting linker struc-
tures in resting lymphocytes may be composed of both ezrin
and moesin, yet be disassembled upon lymphocyte activation
by calpain proteolysis of only ezrin. In support of this theory,
£uorescent microscopy revealed weak ezrin staining homoge-
neously distributed in the cytosol, and moesin found as the
sole ERM protein in the uropods of polarized activated T-
lymphoblasts [36].
In summary, ezrin and the predominant moesin represent
the ERM proteins in blood cells. Cleavage of ezrin by calpain
and insensitivity of moesin to this protease are documented as
biochemically distinguishing features. Calpain-dependent
cleavage of ezrin and persistence of moesin is demonstrated
in the early response of intact lymphocytes to proliferation-
inducing stimulation. Together, these ¢ndings suggest that
di¡erent susceptibility to calpain contributes to the specialized
non-redundant functions of ezrin and moesin.
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